chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Information has been received from a lawyer regarding a case in litigation concerning a female patient of unknown age. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. On or about 25-JUN-2009, the patient was inoculated with ZOSTAVAX (lot number, dosage and route of administration not provided), as recommended for routine adult health maintenance for the prevention of shingles. The ZOSTAVAX did not prevent shingles as intended, and the patient subsequently contracted a persistent strain of herpes zoster, also known as shingles and other complications. On or about 28-SEP-2015, the patient was treated for a blistering vesicular outbreak that was diagnosed as severe shingles. The patient was prescribed valacyclovir hydrochloride (VALTREX) for management of her painful symptoms and chronic pain. On or about 15-OCT-2016, the patient was treated for a blistering vesicular outbreak that was diagnosed as severe shingles. The patient was prescribed gabapentin for management of her painful symptom and chronic pain. The outcome of the events is not recovered. As a direct and proximate result of ZOSTAVAX vaccine, and/or despite receiving ZOSTAVAX for the long-term prevention of shingles, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, and pain and suffering, and other damages. Additional information has been requested.
7 days after vaccination, initially had some redness on the injection spot. It was itchy. Within 2 days it was already spreading to most of the upper arm. By day three it started spreading to chest and other arm.
Pt. was sitting during observation period, became lightheaded. Did not say anything to staff. Pt. fell over out of chair and hit head on the ground. Pt. became responsive approx 1min after staff was at patient side. Pt. was rolled over and became A&O x 3
Flushed, dizzy, diaphoretic: all resolved 1840. reports back to baseline
Right arm (injection site) sore.Currently BREASTFEEDING: Baby had upper respiratory symptoms (congestion and cough) NO fever that started ~6 hours after booster administration and lasted for about 24 hours.
Heartbeat fast - (2 months). Dizzy. Could not stand more than 5 min. Severe flu symptoms (2 wks).
headache; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of HEADACHE (headache) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Unknown) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced HEADACHE (headache). At the time of the report, HEADACHE (headache) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
Lower right abdominal pain with cramping in right glut muscle.  I had my second Moderna vaccine Wednesday 21,April. The first time I experienced this abdominal pain was about 2 to 3 days after the 1st shot. Now, about the same time frame after the second, I have increased abdominal pain in the same area -my right lower abdomen.    Where it was more random, it is now constant.  I thought this was important to report.
This case was reported in a literature article and described the occurrence of uveitis in a 28-year-old female subject who was vaccinated with Hepatitis B (manufacturer unspecified). Previous and/or concurrent vaccination included Salmonella typhi Vi capsular polysaccharide vaccine; manufacturer unspecified; unknown given on an unspecified date. On an unspecified date the subject received 1st dose of Hepatitis B (unknown). Seven days after vaccination with Hepatitis B, the subject experienced uveitis, arthralgia, erythema, nodosum and fever. This case was assessed as medically serious by GSK. This is one of the 32 reported cases (B0662264A till B0662297A) of uveitis which occurred after hepatitis b between 1982 and 2009. It appeared that all subject's recovered, although the treatment for uveitis was not reported. The uveitis occurred in average of 3 days after vaccination in patients without other risk factors or disease that could cause uveitis. This could be consistent with immune complex deposition or nonspecific activation from vaccine adjuvants. Although there was a debate that uveitis occurs because of hepatitis B infection there was evidence that immune complex deposition diseases such as glomerulonephritis and cryoglobulinemia occurred during chronic hepatitis B infection. Furthermore it was possible the surface antigen of the vaccine and the hepatitis B antibodies of the immune response after vaccination formed immune complexes, which initiated the ocular response of uveitis.
I also got covid in Jan2022 after having the booster in Sep2021; I also got covid in Jan2022 after having the booster in Sep2021; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP),. The reporter is the patient.  A 74-year-old patient received BNT162b2 (BNT162B2), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and in Sep2021 as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), SUSPECTED COVID-19 (medically significant) all with onset Jan2022, outcome "unknown" and all described as "I also got covid in Jan2022 after having the booster in Sep2021".  Clinical course: The patient was  interested in a new booster for fall 2022. The patient have had the original vaccines and two boosters, the last booster was in Apr2022. The patient had no side effects from the shots. There was a new covid variant that the boosters the patient have had would not keep the patient from getting covid and it was worse than the ones i got the booster for. The patient also got covid in Jan2022 after having the booster in Sep2021.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
I had a severe soreness in my arm.  Then I had pain in my legs and eyes.  I had a fever, headache and chest congestive. I was very fatigue.  I went to urgent care about it.  They gave me shot to relief the pain.  Then I went to my doctor about it.  She did chest x-ray and diagnosis me with pneumonia.  I was in bed for a least a whole month.
Patient had arm swelling @ injection site, lightheaded, fainting sweating- Patient given 1 dose of EPIPEN.
This spontaneous report as received from a nurse refers to an approximately 15 month old male patient. On 03-MAR-2011, the patient was vaccinated with the first dose of MMR II, lot # 669200/1346Z, therapy type rHA (expiration date, dose, frequency and route not reported). On an unknown date in March 2011, the patient experienced redness, swelling, and injection-site pain after receipt of a dose of MMR II. No treatment was given for adverse event. The patient recovered on an unspecified date, and he was in the practice today ("10-DEC_2013") for his second dose of MMR II. Additional information has been requested.
pt recv vax & devel a sterile abscess @ the inj site;the abscess opened & drained on its own;this is 1 of 2 pt from this facility to devel a sterile abscess p/vax;
no adverse events known, but child was only 11 years old at the time this vaccine was given due to inaccurate information on the consent form filled out by her father.
Within the first 10 minutes of the injection I got a strong twitch in my arm at the injection site. It was sudden and did not last more than a few seconds. After about 30 minutes my face began tingling on the right side. I had Bells Palsy about 3 years ago and it was reminiscent of that event. Luckily it only lasted about an hour.
This spontaneous report as received from a registered nurse refers to a patients with unknown age and sex. Since 02-OCT-2014 patients were vaccinated with VAQTA (lot#, route and dose unknown) which had been exposed to temperatures outside of the recommended range. No adverse experience had been reported. It was not specified if patients sought for medical attention. This is one of several reports received from the same reporter. Additional information has been requested.
Diagnosed with type 1 diabetes. First high glucose reading was take dec 7 2021. Officially diagnosed as type 1 in March of 2022.
A bump and a 3 inch rash at the site of administration of the vaccine; A bump and a 3 inch rash at the site of administration of the vaccine; This spontaneous case from was received on 24-Sep-2020 from other non-health professional via The Agency (reference number: SEQW20-02263) and concerned a patient of an unknown age and gender.  The patient's medical history and concomitant medications were not reported.   On 17-Sep-2020, the patient was vaccinated with Flucelvax QIV (influenza vaccine, subunit influenza virus vaccine polyvalent, dose: 0.5 ml, route of administration: intramuscular, anatomical location: deltoid) for influenza prophylaxis. The batch number reported was 283849 and expiry date was 30-Jun-2021.   On the same day, after receiving Flucelvax QIV, the patient developed a bump and a 3-inch rash at the site of administration of the vaccine. The patient did not receive any treatment measures associated with the events.  On an unspecified date in Sep-2020, the patient recovered from the events.  The reporter did not provide a causality assessment to Flucelvax QIV.   The case was assessed as non-serious.  This case is linked to cases  202004678, 202004696, 202004697, 202004698, 202004699, 202004700, 202004702, 202004703, 202004704, 202004705 and 202004706  due to the same reporter.  Additional non-significant information received on 06-Jan-2021 from other non-health professional via The Agency (reference number: SEQW21-00065) with additional information received on 12-Jan-2021 from other health professional (reference number: SEQW21-00149) (being processed together): Two reporters were added. Reference numbers added. No changes in narrative.  Company comment: A patient of an unknown age and gender was administered Flucelvax QIV vaccine. On the same day, after receiving Flucelvax QIV, the patient developed vaccination site rash and vaccination site mass. The patient's medical history and concomitant medications were not reported. Chronology is plausible. Causality is assessed as possibly related for both events.; Sender's Comments: A patient of an unknown age and gender was administered Flucelvax QIV vaccine. On the same day, after receiving Flucelvax QIV, the patient developed vaccination site rash and vaccination site mass. The patient's medical history and concomitant medications were not reported. Chronology is plausible. Causality is assessed as possibly related for both events.
pt recv vax 19JUL95 & lab eval 3JAN96 revealed lack of seroconversion (IgG=0.11);
pt recv vax 1DEC98 & devel  a rash;pt recovered;
Injection Site: Pain, tenderness and swelling of the lymph nodes (under arm), swelling (hardness), and redness. Other: fatigue; headache; muscle pain; joint pain; chills and fever.
Information has been received from a certified medical assistant concerning a male patient (age unknown) who was vaccinated on an unspecified date with a dose of Pneumovax 23 (655289/0958F).  Subsequently, on an unspecified date, the patient developed injection site redness and swelling and experienced a decreased range of motion of the arm.  The patient sought unspecified medical attention.  At the time of this report, the outcome was unknown.  No product quality complaint involved.  A lot check was requested.  The records of testing prior to release of the lot in question have been rechecked and found to be satisfactory.  The lot complies with the standards of the agency and was released.  Additional information has been requested.
Covid booster; I'm experiencing a headache; whole body stiffness; joint pain; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 57 year-old female patient received bnt162b2 (BNT162B2), administration date 22Nov2021 (Batch/Lot number: unknown) as dose number unknown (booster), 30 ug single for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. Vaccination history included: Covid-19 vaccine (First dose, Primary Immunization series complete but unknown manufacturer), for COVID-19 immunization; Covid-19 vaccine (Seccond dose, Primary Immunization series complete but unknown manufacturer), for COVID-19 immunisation. The following information was reported: IMMUNISATION (non-serious) with onset 22Nov2021, outcome "unknown", described as "Covid booster"; HEADACHE (non-serious) with onset Nov2021, outcome "not recovered", described as "I'm experiencing a headache"; MUSCULOSKELETAL STIFFNESS (non-serious) with onset Nov2021, outcome "not recovered", described as "whole body stiffness"; ARTHRALGIA (non-serious) with onset Nov2021, outcome "not recovered", described as "joint pain".  The lot number for bnt162b2 was not provided and will be requested during follow up.  Additional information: Event took place after use of product. After receiving the Covid booster on 22Nov2021, several hours afterwards and continuing to now, I'm experiencing a headache and whole body stiffness and joint pain.
This is a spontaneous report from a non-contactable consumer (parent). A female patient (daughter) of unspecified age received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Batch/Lot number: unknown), via an unspecified route of administration on an unspecified date as single dose for COVID-19 immunization. Medical history of the patient was not reported. Patient was not taking any concomitant medication [no concomitant list]. Patient previously received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Batch/Lot number: unknown), via an unspecified route of administration on an unspecified date as single dose for COVID-19 immunization and experienced joints and muscles hurt. On an unspecified date, after receiving second dose of vaccination, patient condition got worsened and her Joints swelled up-feet, hands, ankles. Reporter stated it was not muscle it was more joints. Doctor put her on steroid pills, and within the next day, all her symptoms went away. When she got off the steroid, everything came back just the way it was. The doctor tried to refer her a rheumatologist but have to wait a year to get an appointment. Reporter assessed the event as non-serious. Treatment received included steroid pills. Outcome of the events were unknown. No follow-up attempts are possible, information about lot/batch number cannot be obtained.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202100929336
MUSCLE TIGHTNESS; JOINT DISCOMFORT; FEVER; This spontaneous report received from a patient concerned a male of unspecified age. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose was not reported, administered on 08-MAR-2021 for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported. On 21-MAR-2021, the subject experienced muscle tightness. On 21-MAR-2021, the subject experienced joint discomfort. On 21-MAR-2021, the subject experienced fever. Laboratory data included: Body temperature (NR: not provided) 99.1 F. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from fever, muscle tightness, and joint discomfort. This report was non-serious.
pain at the arm of the injection; vaccine exposure during pregnancy; This spontaneous prospective pregnancy case was reported by a consumer and describes the occurrence of MATERNAL EXPOSURE DURING PREGNANCY (vaccine exposure during pregnancy) and INJECTION SITE PAIN (pain at the arm of the injection) in a 36-year-old female patient (gravida 3) who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 013M20A and 012A21A) for COVID-19 vaccination.     The patient's past medical history included Induced abortion (blood problem , the baby did not come out, had to have surgery) in 2018, Spontaneous abortion in 2012, Hemochromatosis and Blood disorder NOS. Concurrent medical conditions included Allergy NOS. Concomitant products included MINERALS NOS, VITAMINS NOS (PRENATAL VITAMINS [MINERALS NOS;VITAMINS NOS]) for Pregnancy, ASPIRIN [ACETYLSALICYLIC ACID] for an unknown indication.   On 02-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. The patient's last menstrual period was on 28-Jan-2021 and the estimated date of delivery was 03-Oct-2021. On 02-Feb-2021, the patient experienced MATERNAL EXPOSURE DURING PREGNANCY (vaccine exposure during pregnancy). On an unknown date, the patient experienced INJECTION SITE PAIN (pain at the arm of the injection). The patient received mRNA-1273 (Moderna COVID-19 Vaccine) during pregnancy.  On 02-Feb-2021, MATERNAL EXPOSURE DURING PREGNANCY (vaccine exposure during pregnancy) had resolved. At the time of the report, INJECTION SITE PAIN (pain at the arm of the injection) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 29-Jan-2021, Pregnancy test: Positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant Medications include unspecified allergy medicine.  No treatment medications were reported.   This case was linked to MOD-2021-039519 (Patient Link).
Fever to 103.7, headache, chills, anorexia, inflammation at injection site
Child had infantile spasms, 1 day, post vax, 1st Tetramune vaccine. He was hospitalized for 4 days for observation. Treated with steroids. Autism began to develop at 12 months when child lost ability to speak. Dx'd as mild autism at 2 years. Currently in therapy.
This spontaneous report as received from a 67 year old female patient with allergy to penicillin, refers to herself. No pertinent medical history was reported. On 27-OCT-2014 patient was vaccinated with PNEUMOVAX 23 (dose, route, lot # and expiration date were not provided) in the upper left arm at her local pharmacy. No concomitant medications were reported. On 28-OCT-2014, the next day after receiving the vaccine the patient developed swelling and redness at the injection site up to her lymph nodes under her arm and feels a complete achiness throughout her entire body. The patient sought medical attention via office visit on 29-OCT-2014. They physician advised her to report adverse effects that she developed as a result of receiving the PNEUMOVAX 23 vaccine and to take ADVIL and to use an ice pack for the swelling. No lab diagnostics studies were performed. At the time of the report the patient did not recover from the events. The events was considered to be related to PNEUMOVAX 23. Additional information has been requested.
23 HOURS AFTER VACCINE DEVELOPED LIP SWELLING , BODY PRURITIS, AND BILATERAL BLOTCHY HANDS. ABDOMINAL PERIUMBILICAL PAIN. SYMPTOMS LASTED 12 HOURS.  STARTED ON OZEMPIC 7 WEEKS AGO AND HAD SAME ABDOMINAL PAIN 3 WEEKS AGO BUT NONE OF THE OTHER SYMPTOMS. THIS ABDOMINAL PAIN MAY NOT BE RELATED.  IMPRESSION: PROBABLE ALLERGY TO MODERNA.  PCP WAS NOTIFIED BY VACCINE CLINC.  PATIENT ADVISED TO SEE ALLERGIST IF HE CHOOSES TO PROCEED WITH SECOND DOSE OF MODERNA.
Fever to 39 degrees C (positive), severe headache, delusions, red, swollen injection site.  2/6/07 Received medical records from hospital which reveal patient experienced fever & delirium s/p pneumovax & flu vax.  Admitted from 1/24-1/28/07.  Exam revealed confusion. Admit dx was pneumonitis & was started on IV antibiotics.  Fever resolved & developed warmth & erythema of right arm w/pain on motion right shoulder which improved w/Benadryl.   FINAL DX: Fever w/o source; possible inflammatory response to Pneumovax immunization vs Flu vax.
Noticed another significant improvement in my stamina and alertness; suffering for two days with exhaustion from the vaccine; This spontaneous case was reported by a patient and describes the occurrence of THERAPEUTIC RESPONSE UNEXPECTED (Noticed another significant improvement in my stamina and alertness) and FATIGUE (suffering for two days with exhaustion from the vaccine) in an elderly male patient who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis.     The patient's past medical history included Bedridden and Gait disturbance. Concurrent medical conditions included Chronic fatigue syndrome (Chronic fatigue immune dysfuction syndrome), Cerebral disorder (fogged brain, searching for words and difficulty with simple math) and Memory loss.    On 26-Sep-2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. On an unknown date, the patient experienced THERAPEUTIC RESPONSE UNEXPECTED (Noticed another significant improvement in my stamina and alertness) and FATIGUE (suffering for two days with exhaustion from the vaccine). At the time of the report, THERAPEUTIC RESPONSE UNEXPECTED (Noticed another significant improvement in my stamina and alertness) and FATIGUE (suffering for two days with exhaustion from the vaccine) outcome was unknown.            Concomitant and treatment medication were not reported.  After Spikevax administration on 26-Sep-2023, the patient had noticed another significant improvement in stamina and alertness. The patient felt it was important for research in the area of vaccine and the effect on chronic fatigue dysfunction syndrome.   This case was linked to MOD-2022-583908 (Patient Link).
At 11pm I was awakened due to my rapid heart rate.  I began to feel nauseous, had jaw pain and pain in my left shoulder. I went  to the hospital where I was diagnosed with A-Fib.  I was admitted overnight and discharged the next day.
extremely sore left arm/"extreme pain in his left arm" where he received the Pfizer COVID-19 vaccine shot for the past 5 months; This is a spontaneous report from a contactable consumer (patient). A 72-year-old male patient received bnt162b2 (COMIRNATY), via an unspecified route of administration, administered in arm left on 06May2021 (Batch/Lot number was not reported) (at age 72-years-old) as dose number unknown, single for covid-19 immunisation.  Medical history included glaucoma from 1990 and ongoing. There were no concomitant medications. The patient experienced extremely sore left arm/ extreme pain in his left arm where he received the Pfizer covid-19 vaccine shot for the past 5 months. Patient wanted to find out how long he will have this reaction. He was scared to get the booster because he is scared he may get crippled in the arm. Stated that pain management wanted him to get X-rays because he knew what it was from and told them no. Patient reported that within 24 hours of getting the shot that he started having pain on May2021. Treatment included muscle relaxers. Outcome of the event was not recovered.  Follow-up attempts are completed; information about lot/batch number cannot be obtained. No further information is expected.
hives p/flu vax 10OCT97 faces & lips swollen;hives inside mouth-wheezing-SOB;